Kenvue, Inc. ( (KVUE)) has released its Q3 earnings. Here is a breakdown of the information Kenvue, Inc. presented to its investors. Kenvue, Inc., the world’s largest pure-play consumer health ...

Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. Is it time to buy ...

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a quarterly dividend of $0.205 ...

(Reuters) -Hedge fund Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster growth is the reason for the stock's underperformance.

Kenvue said it now expects annual net sales to grow closer to the lower end of its forecast of 1% to 3% growth. It reaffirmed its annual per share profit forecast of between $1.10 and $1.20.

During the last three months, 10 analysts shared their evaluations of Kenvue KVUE, revealing diverse outlooks from bullish to bearish. The table below provides a concise overview of recent ratings ...

SKILLMAN, N.J. (AP) — SKILLMAN, N.J. (AP) — Kenvue Inc. (KVUE) on Thursday reported third-quarter profit of $383 million. On a per-share basis, the Skillman, New Jersey-based company said it ...

Kenvue, Inc. (KVUE – Research Report), the Technology sector company, was revisited by a Wall Street analyst yesterday. Analyst Anna Lizzul from Bank of America Securities reiterated a Buy ...

Whether it's rethinking brand strategies, tweaking pricing, or even spinning off its weaker segments, Starboard is clearly aiming for a shake-up to jolt Kenvue back to life. Warning! GuruFocus has ...

Kenvue, Inc. is a consumer health company. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold ...

Kenvue Inc., the owner of Tylenol and Neutrogena, reported sales that trailed estimates after its skin health and beauty category slowed. Organic sales rose 0.9% in the three months ended Sept.

Shares of Kenvue (NYSE: KVUE) got a nice bounce on Monday ... For decades, consumer health took a back seat to Johnson & Johnson's rapidly growing medical technology and pharmaceutical segments.